NVSNovartis PharmaceuticalsRunning, no new patients
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 259 (final count)
- Started
- Oct 22, 2013
- Main results expected
- Feb 26, 2027
- Fully finished
- Feb 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose limiting toxicities (DLTs) - Phase lb only
Measured over: 28 days
Safety and tolerability
Measured over: Average 18 months
PK profiles of LEE011 and letrozole
Measured over: 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT01872260 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC